Curis, Inc.

Is Curis, Inc. technically bullish or bearish?

As of September 2, 2025, Curis, Inc. is in a mildly bearish trend, indicated by a bearish daily moving average and weekly KST, despite some positive momentum from the weekly MACD and RSI, while significantly underperforming the S&P 500 with a year-to-date return of -43.79%.

As of 2 September 2025, the technical trend for Curis, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, supported by a bearish daily moving average and a bearish weekly KST. However, the weekly MACD and RSI are mildly bullish and bullish, respectively, indicating some positive momentum. The Bollinger Bands show a bearish signal on the weekly timeframe. In terms of performance, Curis has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -43.79% compared to the S&P 500's 12.22%, and a one-year return of -70.65% versus 17.14%.

How big is Curis, Inc.?

As of Jun 18, Curis, Inc. has a market capitalization of 24.69 million and reported net sales of 11.21 million with a net profit of -42.13 million over the latest four quarters. Shareholder's funds are at -6.00 million, with total assets of 42.13 million.

As of Jun 18, Curis, Inc. has a market capitalization of 24.69 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 11.21 million, while the sum of net profit for the same period is -42.13 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -6.00 million, and total assets amount to 42.13 million.

What does Curis, Inc. do?

Curis, Inc. is a biotechnology company focused on developing cancer treatments, with a market cap of approximately $24.69 million. As of March 2025, it reported net sales of $2 million and a net loss of $11 million.

Overview:<BR>Curis, Inc. is a biotechnology company focused on developing and commercializing drug candidates for the treatment of cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 24.69 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.93<BR>- Return on Equity: 637.64%<BR>- Price to Book: -3.74<BR><BR>Contact Details:<BR>- Address: 128 SPRING STREET, BUILDING C, SUITE 500, LEXINGTON MA: 02421<BR>- Tel: 1 617 5036500<BR>- Website: http://www.curis.com/

Should I buy, sell or hold Curis, Inc.?

Who are in the management team of Curis, Inc.?

As of March 2022, the management team of Curis, Inc. includes Martyn Greenacre (Independent Chairman), James Dentzer (President and CEO), and Independent Directors Kenneth Kaitin, Lori Kunkel, and Marc Rubin. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Curis, Inc. includes the following individuals:<BR><BR>- Mr. Martyn Greenacre, who serves as the Independent Chairman of the Board.<BR>- Mr. James Dentzer, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Kenneth Kaitin, who is an Independent Director.<BR>- Dr. Lori Kunkel, who is also an Independent Director.<BR>- Dr. Marc Rubin, who serves as an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.